ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report
Back
John Wilkinson

Dr John Wilkinson

Chief Technical Officer

PhD, BSc Hons

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer. 

John graduated from the University of Portsmouth (BSc Hons) in 1988 and took up a position at the Wellcome Research Laboratories in England and subsequently completed a PhD in HIV-1 Immunovirology from the University of NSW.  An early career in academia, with post-doctoral positions at the Chelsea and Westminster Hospital and Imperial College London in the UK, were followed with an appointment at the Westmead Millennium Institute as a Senior Scientist. His research interests during this time included Drug Discovery and Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that resulted in numerous peer-reviewed publications and presentations at both national and international conferences.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs. 

At Noxopharm, John will manage the drug manufacture and supply, support the drug development of novel molecules arising from the company’s drug pipeline, in addition to providing regulatory and clinical support across Noxopharm’s clinical portfolio.